GSK 2018682
Alternative Names: 2018682; GSK2018682Latest Information Update: 18 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class
- Mechanism of Action Sphingosine 1 phosphate receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Multiple-sclerosis(In volunteers) in Australia (PO)
- 03 Nov 2011 GlaxoSmithKline completes a phase I trial in Healthy volunteers in Australia (NCT01466322)
- 01 Mar 2011 GlaxoSmithKline completes a phase I trial in Healthy volunteers in Australia (NCT01431937)